{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:20:10Z","timestamp":1791872410695,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2020.03.017","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T16:13:52Z","timestamp":1584807232000},"page":"3560-3569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1766-3153","authenticated-orcid":false,"given":"Lee-Jah","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hedrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Jordanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep S.","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.03.017_b0005","unstructured":"Centers for Disease Control and Prevention, Meningococcal Disease in Other Countries."},{"key":"10.1016\/j.vaccine.2020.03.017_b0010","unstructured":"Centers for Disease Control and Prevention, Meningococcal Disease: Technical and Clinical Information."},{"key":"10.1016\/j.vaccine.2020.03.017_b0015","unstructured":"Invasive meningococcal disease, Annual Epidemiological Report for 2017. Stockholm: ECDC; 20192017."},{"key":"10.1016\/j.vaccine.2020.03.017_b0020","series-title":"Neisseria meningitidis: Advanced Methods and Protocols","first-page":"1","article-title":"Neisseria meningitidis: Biology, Microbiology, and Epidemiology","author":"Rouphael","year":"2012"},{"key":"10.1016\/j.vaccine.2020.03.017_b0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.vaccine.2020.03.017_b0030","unstructured":"Centers for Disease Control and Prevention, Causes and Spread to Others. Meningococcal Disease."},{"key":"10.1016\/j.vaccine.2020.03.017_b0035","unstructured":"Centers for Disease Control and Prevention, Age as a Risk Factor. Meningococcal Disease 2017"},{"key":"10.1016\/j.vaccine.2020.03.017_b0040","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/cid\/cix993","article-title":"Current Epidemiology and Trends in Meningococcal Disease\u2014United States, 1996\u20132015","volume":"66","author":"MacNeil","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.017_b0045","unstructured":"European Centre for Disease Prevention and Control, Factsheet about meningococcal disease. 2019."},{"issue":"14","key":"10.1016\/j.vaccine.2020.03.017_b0050","article-title":"Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017","volume":"24","author":"Krone","year":"2019","journal-title":"Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin"},{"key":"10.1016\/j.vaccine.2020.03.017_b0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijid.2019.05.006","article-title":"Epidemiological burden of meningococcal disease in Latin America: A systematic literature review","volume":"85","author":"Vespa Presa","year":"2019","journal-title":"International Journal of Infectious Diseases."},{"key":"10.1016\/j.vaccine.2020.03.017_b0060","unstructured":"Inc. SP, Menactra\u00ae vaccine [Prescribing Information]. Swiftwater, PA."},{"key":"10.1016\/j.vaccine.2020.03.017_b0065","unstructured":"Centers for Disease Control and Prevention, Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2013:1-22."},{"key":"10.1016\/j.vaccine.2020.03.017_b0070","unstructured":"Nimenrix\u00ae Summary of Product Characteristics 2019."},{"key":"10.1016\/j.vaccine.2020.03.017_b0075","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/INF.0b013e318268dfe4","article-title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Infants and Toddlers: Three Multicenter Phase III Studies","volume":"31","author":"Pina","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.03.017_b0080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/CVI.05460-11","article-title":"Comparative Study of Different Sources of Pertussis Toxin (PT) as Coating Antigens in IgG Anti-PT Enzyme-Linked Immunosorbent Assays","volume":"19","author":"Kapasi","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.03.017_b0085","first-page":"108","article-title":"Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay","volume":"10","author":"Opalka","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2020.03.017_b0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jpids\/pit058","article-title":"Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10\u201325 Years of Age","volume":"3","author":"Halperin","year":"2014","journal-title":"J Pediatric Infect Dis Soc."},{"key":"10.1016\/j.vaccine.2020.03.017_b0095","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/INF.0b013e31824f34e6","article-title":"Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom","volume":"31","author":"Findlow","year":"2012","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2020.03.017_b0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00431-012-1924-0","article-title":"Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2\u201310-year-old children: results of an open, randomised, controlled study","volume":"172","author":"Knuf","year":"2013","journal-title":"Eur J Pediatr."},{"key":"10.1016\/j.vaccine.2020.03.017_b0105","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/CVI.00068-09","article-title":"Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A\/C polysaccharide vaccine in adults","volume":"16","author":"Findlow","year":"2009","journal-title":"Clin Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2020.03.017_b0110","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays - the role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.017_b0115","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","volume":"15","author":"Findlow","year":"2019","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2020.03.017_b0120","unstructured":"Practices ACoI, Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019."},{"key":"10.1016\/j.vaccine.2020.03.017_b0125","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/21645515.2018.1528831","article-title":"Meningococcal disease in adolescents and young adults: a review of the rationale for prevention through vaccination","volume":"15","author":"Burman","year":"2019","journal-title":"Human Vaccines & Immunotherapeutics."},{"key":"10.1016\/j.vaccine.2020.03.017_b0130","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.281.20.1906","article-title":"Risk of meningococcal infection in college students","volume":"281","author":"Harrison","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.03.017_b0135","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1001\/jama.286.6.688","article-title":"Risk factors for meningococcal disease in college students","volume":"286","author":"Bruce","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.03.017_b0140","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.vaccine.2017.03.066","article-title":"Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines","volume":"35","author":"Beresford","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.017_b0145","series-title":"Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States","author":"Centers for Disease Control and Prevention","year":"2019"},{"key":"10.1016\/j.vaccine.2020.03.017_b0150","unstructured":"Inc. P., Prevnar 13\u00ae (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) [Prescribing Information]."},{"key":"10.1016\/j.vaccine.2020.03.017_b0155","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1128\/CVI.00474-14","article-title":"Safety and Immunogenicity of Tetanus-Diphtheria-Acellular Pertussis Vaccine Administered to Children 10 or 11 Years of Age","volume":"21","author":"Marshall","year":"2014","journal-title":"Clin Vaccine Immunol."},{"key":"10.1016\/j.vaccine.2020.03.017_b0160","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1016\/j.vaccine.2019.07.015","article-title":"Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP","volume":"37","author":"Decker","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.017_b0165","unstructured":"ClinicalTrials.gov."},{"key":"10.1016\/j.vaccine.2020.03.017_b0170","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1016\/j.vaccine.2018.04.034","volume":"36","author":"Rivera","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.017_b0175","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2014.09.064","article-title":"Immunogenicity and reactogenicity of Infanrix\u2122 when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix\u2122 and Pediarix\u2122","volume":"33","author":"Leonardi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.017_bib176","first-page":"1","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","author":"Findlow","year":"2019","journal-title":"Hum Vaccine Immunother"},{"key":"10.1016\/j.vaccine.2020.03.017_bib177","first-page":"1","article-title":"Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recommendations and reports\u202f: Morbidity and mortality weekly report Recommendations and reports"},{"key":"10.1016\/j.vaccine.2020.03.017_bib178","unstructured":"European Medicines Agency. Assessment report for Menveo."},{"key":"10.1016\/j.vaccine.2020.03.017_bib179","unstructured":"European Medicines Agency. Assessment report: Nimenrix."},{"issue":"18","key":"10.1016\/j.vaccine.2020.03.017_bib180","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1016\/j.vaccine.2010.02.045","article-title":"Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines","volume":"28","author":"Arguedas","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:48Z","timestamp":1759401708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20303704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X20303704"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.017","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}